Multiple Sclerosis-Market Insight, Epidemiology and Market Forecast-2027
- March 2018
- 100 pages
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Multiple Sclerosis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2016-2027
Multiple Sclerosis- Disease Understanding and Treatment Algorithm
The DelveInsight Multiple Sclerosis market report gives the thorough understanding of the Multiple Sclerosis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Multiple Sclerosis in the US, Europe, and Japan.
Multiple Sclerosis Epidemiology
The Multiple Sclerosis (MS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by Gender [male/female], age group [19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years], sub-types [Relapsing Remitting MS, Primary Progressive MS and Progressive relapsing MS] and Expanded disability status scale (EDSS) [0.0-1.5, 2.0-3.5, 4.0-5.5, 6.0-7.5 and 8.0-9.5].
According to DelveInsight, the prevalent population of Multiple Sclerosis was estimated to be 1.98 Million [7MM] in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. United States accounts for the highest MS Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. In United States, the peak prevalence has been observed in patients aged 4549 years in both female and male participants.
Multiple Sclerosis Drug Chapters
This segment of the Multiple Sclerosis report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The drugs marketed for the treatment of mainly include disease-modifying therapies (DMT) Copaxone , Tecfidera , Gilenya , Tysabri , Avonex, Aubagio , Lemtrada , Ocrevus , Rebif , Betaseron , Extavia , Plegridy , Fampyra , and Zinbryta . Detailed chapters for all of these drugs, along with the upcoming therapies i.e., [Siponimod (Novartis), Ponesimod (Johnson and Johnson), Ozanimod (Celgene), Ofatumumab (Novartis), Ublituximab (TG Therapeutics), ALKS 8700 (Alkermes Plc), and Mavenclad (Merck KgaA)] have been covered in the report.
Multiple Sclerosis Market Outlook
The Multiple Sclerosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criterias, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Multiple Sclerosis was estimated to be USD 21.25 billion in 2016, and is expected to increase at a CAGR of XX% from 2016-2027.
Multiple Sclerosis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The market size of Multiple Sclerosis includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.
Multiple Sclerosis Report Insights
Market Size and Trends
Impact of upcoming Therapies
Multiple Sclerosis Report Key Strengths
10 Year Forecast
Highly Analyzed Market
Key Cross Competition
Multiple Sclerosis Report Assessment
Current Treatment Practices
Detailed Pipeline Product Profiles
Market Drivers and Barriers
This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Multiple Sclerosis market
Organize sales and marketing efforts by identifying the best opportunities for Multiple Sclerosis market
To understand the future market competition in the Multiple Sclerosis market.
Have query on this report?Make an Enquiry
2. Multiple Sclerosis Market Overview at a Glance 2
2.1. Market Share Distribution of Multiple Sclerosis in 2017 2
2.2. Market Share Distribution of Multiple Sclerosis in 2027 2
3. Disease Background and Overview: Multiple Sclerosis (MS) 13
Table 2: Total Prevalent Population of Multiple Sclerosis in 7 MM (2016-2027) 33
Table 3: Prevalent Population of Multiple Sclerosis in 7MM- By Region (2016-2027) 34
Table 4: Prevalent Population of Multiple Sclerosis in United States (2016-2027) 39
Table 5: Sex-Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 40
Table 6: Sub-type Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 41
More from Pharmaceutical
PharmaceuticalChinese Markets for Mental Illness Drugs
PharmaceuticalChinese Markets for Anti-Dermatomycosis Skin Drugs
PharmaceuticalChinese Markets for Incretion Drugs
PharmaceuticalChinese Markets for Hypertension Drugs
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017